Sector News

Horizon partners with MIT for crowdsourced rare disease solutions, narrows to 5 finalists

September 19, 2021
Life sciences

Getting started is often the most difficult part—and that’s especially true in rare diseases and diagnoses. Patients and families often spend many years searching for their diagnosis starting point.

For Horizon Therapeutics’ first innovation challenge, it took that struggle to heart and asked for technology-based rare disease solutions that result in faster or more accurate diagnoses.

The diagnosis-connected challenge is Horizon’s first, working with Massachusetts Institute of Technology’s Solve, its global solution-sourcing platform, but not last. Every year going forward, Horizon will come up with a new challenge question—sourcing rare disease solutions around things like transportation, electronic health records and caregiver support for example, Holly Copeland, senior director of corporate social responsibility at Horizon, said.

“We all kind of exist within our own echo chambers and networks, but we’re humble enough to recognize that all of the best solutions or innovative ideas don’t exist only within the space we inhabit,” she said. “We loved the idea of partnering with MIT to reveal ideas from all over the world that we hadn’t thought of before to help foster and develop them.”

Now narrowed down from 50 entries to five finalists, the winner of the Horizon Prize will be chosen by a panel of 10 judges, which includes a global group of investors, parents of children with rare diseases and patient advocacy groups as well as one Horizon judge.

The hopefuls include a data-driven “hackathon” provider, a patient data hub manager, an African healthcare decision optimizer, a rare disease therapy manager for underrepresented communities and a genetic algorithm provider.

The winner or winners—the contest allows up to two—will be revealed Monday, with a $150,000 prize purse and continuing mentorship, resources and expert advice as needed to bring the solutions to market.

Still even the “losing” finalists will win. Horizon and MIT plan to offer continued support, Copeland said.

“The mission of Horizon is to identify, develop and create new treatments for rare disease … Our intention here is to marry the mission of the company with the work we’re doing to create healthy ecosystems that also help to create solutions for rare disease patients,” she said.

by Beth Snyder Bulik

Source: fiercepharma.com

comments closed

Related News

October 23, 2021

Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch

Life sciences

As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.

October 23, 2021

GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody

Life sciences

The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.

October 23, 2021

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.

Send this to a friend